Shank Scaffold Protein Neurons <table class="infobox infobox-cell"> <tr> <th class="infobox-header" colspan="2">Shank Scaffold Protein Neurons</th> </tr> <tr> <td class="label">Location </td> <td>Postsynaptic density of glutamatergic synapses</td> </tr> <tr> <td class="label">Protein Family </td> <td>SHANK1, SHANK2, SHANK3</td> </tr> <tr> <td class="label">Expression </td> <td>Cortex, hippocampus, striatum, cerebellum</td> </tr> <tr> <td class="label">Primary Function </td> <td>PSD scaffold, receptor clustering, spine morphogenesis</td> </tr> <tr> <td class="label">Disease Relevance </td> <td>Autism, Phelan-McDermid syndrome, schizophrenia, Alzheimer's disease</td> </tr> <tr> <td class="label">Domain</td> <td>Position</td> </tr> <tr> <td class="label">ANK repeats</td> <td>N-terminal</td> </tr> <tr> <td class="label">SH3 domain</td> <td>Central</td> </tr> <tr> <td class="label">PDZ domain</td> <td>Central</td> </tr> <tr> <td class="label">Proline-rich region</td> <td>C-terminal</td> </tr> <tr> <td class="label">SAM domain</td> <td>C-terminal</td> </tr> <tr> <td class="label">Gene</td> <td>Mutation Type</td> </tr> <tr> <td class="label">SHANK1</td> <td>Point mutations, deletions</td> </tr> <tr> <td class="label">SHANK2</td> <td>De novo truncating, missense</td> </tr> <tr> <td class="label">SHANK3</td> <td>Deletions (22q13), truncating</td> </tr> </table>
...
Shank Scaffold Protein Neurons <table class="infobox infobox-cell"> <tr> <th class="infobox-header" colspan="2">Shank Scaffold Protein Neurons</th> </tr> <tr> <td class="label">Location </td> <td>Postsynaptic density of glutamatergic synapses</td> </tr> <tr> <td class="label">Protein Family </td> <td>SHANK1, SHANK2, SHANK3</td> </tr> <tr> <td class="label">Expression </td> <td>Cortex, hippocampus, striatum, cerebellum</td> </tr> <tr> <td class="label">Primary Function </td> <td>PSD scaffold, receptor clustering, spine morphogenesis</td> </tr> <tr> <td class="label">Disease Relevance </td> <td>Autism, Phelan-McDermid syndrome, schizophrenia, Alzheimer's disease</td> </tr> <tr> <td class="label">Domain</td> <td>Position</td> </tr> <tr> <td class="label">ANK repeats</td> <td>N-terminal</td> </tr> <tr> <td class="label">SH3 domain</td> <td>Central</td> </tr> <tr> <td class="label">PDZ domain</td> <td>Central</td> </tr> <tr> <td class="label">Proline-rich region</td> <td>C-terminal</td> </tr> <tr> <td class="label">SAM domain</td> <td>C-terminal</td> </tr> <tr> <td class="label">Gene</td> <td>Mutation Type</td> </tr> <tr> <td class="label">SHANK1</td> <td>Point mutations, deletions</td> </tr> <tr> <td class="label">SHANK2</td> <td>De novo truncating, missense</td> </tr> <tr> <td class="label">SHANK3</td> <td>Deletions (22q13), truncating</td> </tr> </table>
Shank proteins (Shank1-3) are master scaffolding proteins that form the structural backbone of the postsynaptic density (PSD) in glutamatergic synapses. Neurons expressing Shank proteins organize NMDA receptor, AMPA receptor, and mGluR signaling complexes, making them critical for synaptic function, plasticity, and neurodevelopmental/neurodegenerative disease pathogenesis.
Overview
Mermaid diagram (expand to render)
Shank Protein Family
SHANK1 SHANK1 is predominantly expressed in the cerebral cortex and hippocampus: [@hung2008]
Isoforms : Multiple splice variants with varying PDZ domain inclusion
Expression pattern : Highest in forebrain excitatory neurons
Spine regulation : Promotes mature mushroom spine formation
Behavioral phenotype : SHANK1 knockout mice show enhanced learning but impaired social interaction
SHANK2 SHANK2 (also known as ProSAP1) has diverse roles in synaptic development: [@berkel2010]
Early expression : Critical for synaptogenesis timing
Cerebellar expression : High levels in Purkinje cells
Mitochondrial links : SHANK2 variants affect mitochondrial function
Autism association : Multiple de novo mutations identified
SHANK3 SHANK3 (ProSAP2) is the predominant isoform in striatum and the most clinically significant: [@durand2007]
Striatal enrichment : Critical for basal ganglia function
Phelan-McDermid syndrome : 22q13.3 deletion syndrome
Multiple promoters : Six promoters enable complex regulation
Isoform switching : Developmental changes in isoform expression
Molecular Architecture
Domain Structure Each Shank protein contains five conserved domains: [@baron2006]
Protein Interaction Network Shank proteins serve as the central hub of the PSD:
Vertical linkage : GKAP → PSD-95 → NMDA/AMPA receptors
Horizontal linkage : Homer → mGluR5 → IP3R (ER calcium)
Cytoskeletal linkage : Cortactin/Abp1 → F-actin → spine stability
Self-assembly : SAM domains form sheets stabilizing the PSD lattice
Role in Neurodevelopmental Disorders
Autism Spectrum Disorder Shank gene mutations are among the most replicated genetic findings in autism: [@leblond2014]
Mechanisms of synaptic dysfunction :
Reduced PSD-95 recruitment → Impaired NMDA receptor anchoring
Disrupted Homer-mGluR5 coupling → Altered calcium signaling
Defective actin linking → Immature, filopodia-like spines
Impaired SHANK multimerization → Fragmented PSD structure
Phelan-McDermid Syndrome 22q13.3 deletion syndrome results in complete SHANK3 haploinsufficiency: [@phelan2012]
Core features : Neonatal hypotonia, global developmental delay, absent/minimal speech
Autism features : Social communication deficits, repetitive behaviors
Medical comorbidities : Seizures, GI dysfunction, renal abnormalities
Treatment approaches : IGF-1 trials, oxytocin, behavioral therapy
Schizophrenia SHANK variants contribute to schizophrenia risk: [@gauthier2010]
SHANK2 associations : Multiple GWAS hits
SHANK3 rare variants : Truncating mutations in schizophrenia cohorts
Synaptic pathology : Reduced PSD-95, altered Shank expression in postmortem brain
NMDA receptor hypofunction : Disrupted Shank-NMDA linkage contributes to glutamate hypothesis
Role in Neurodegenerative Disease
Alzheimer's Disease Shank protein alterations occur in AD: [@roselli2009]
Early synaptic loss : Shank3 loss precedes overt neurodegeneration
Aβ toxicity : Oligomeric Aβ disrupts Shank-PSD95 interactions
Synaptic marker : Reduced Shank correlates with cognitive decline
Therapeutic target : Preserving Shank scaffolds may protect synapses
Mechanisms :
Calpain-mediated Shank cleavage during excitotoxicity
Aβ-induced oxidative damage to PSD proteins
Tau pathology impairs axonal transport of Shank mRNA
Reduced BDNF signaling decreases Shank expression
Huntington's Disease Striatal Shank3 expression is affected in HD:
Mutant huntingtin : Interferes with Shank3 transcription
Cortico-striatal synapse loss : Shank scaffolds disrupted
mGluR5 dysregulation : Impaired Homer-Shank coupling
Therapeutic Implications
Gene Therapy Approaches
SHANK3 gene replacement : AAV-mediated delivery in preclinical models
CRISPR activation : Upregulating endogenous SHANK3 expression
Antisense oligonucleotides : Modulating splice variants
Pharmacological Targets
IGF-1 : Clinical trials in Phelan-McDermid syndrome
mGluR5 modulators : Targeting Homer-Shank-mGluR5 complex
Actin stabilizers : Enhancing spine stability through Shank-actin linkage
Synaptic Protection in AD
BDNF enhancement : Upregulates Shank expression
Antioxidant strategies : Prevent oxidative Shank damage
Calpain inhibitors : Block pathological Shank cleavage
See Also
[PSD-95 — Primary scaffold partner
[Autism Spectrum Disorder — Primary disease association](/diseases/autism)autism)
[Alzheimer's Disease — Neurodegeneration context](/diseases/alzheimers-disease)neurodegeneration)
[Synaptic Plasticity — Related mechanism](/genes/rel)
[Homer Proteins — Scaffold interaction partner](/content/proteins)
](/diseases/psd-95-—-primary-scaffold-partner
Show full description